Therefore, we undertook a retrospective study of consecutive patients with HER2-positive breast cancer referred to a dedicated cardio-oncology service in a quaternary care institution managed using a strategy of permissive cardiotoxicity. The gene discussed is ERBB2; the disease is breast cancer.